Effects of receptor for advanced glycation endproducts on microvessel formation in endometrial cancer

BMC Cancer. 2016 Feb 12:16:93. doi: 10.1186/s12885-016-2126-3.

Abstract

Background: The receptor for advanced glycation endproducts (RAGE) and microvascular status both play a critical role in cancer progression. However, the crosstalk between RAGE and microvascular formation in endometrial cancer remains largely unknown.

Methods: RAGE expression and microvessel density were examined in 20 cases of normal endometrial tissue, 37 cases of well-differentiated endometrial cancer tissue, and 35 cases of poorly-differentiated endometrial cancer tissue. Regression analysis was used to examine the relationship between RAGE and microvessel density. The knockdown of RAGE was achieved using a small interfering RNA in HEC-1A endometrial cancer cells. A xenografted tumour model was used to evaluate RAGE-mediated microvascular formation and proliferation of endometrial cancer cells.

Results: It was shown that (i) RAGE expression gradually increased in normal endometrium, well-differentiated endometrial cancer, and poorly-differentiated endometrial cancer, respectively; (ii) a positive correlation existed between RAGE and microvessel density in human endometrial cancer samples; (iii) RAGE knockdown was effective in decreasing microvessel formation in xenografted tumour models; and (iv) RAGE knockdown can significantly inhibit the proliferation of endometrial cancer cells in vivo.

Conclusions: These results indicate that RAGE may be a potential trigger in microvascular formation and proliferation in the development of endometrial cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Animals
  • Cell Line, Tumor
  • Cell Proliferation / genetics*
  • Endometrial Neoplasms / genetics*
  • Endometrial Neoplasms / metabolism
  • Endometrial Neoplasms / pathology
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mice
  • Microvessels / metabolism
  • Microvessels / pathology*
  • Middle Aged
  • Receptor for Advanced Glycation End Products / biosynthesis
  • Receptor for Advanced Glycation End Products / genetics*
  • Transfection
  • Xenograft Model Antitumor Assays

Substances

  • Receptor for Advanced Glycation End Products